• SHRG’s Elepreneurs subsidiary uses platform from Verb Technology for launch in United States; Canadian unveil to follow
• Five-star interactive sales marketing tool designed to help Elepreneurs build on sales gains
• For Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of comparable period in 2018

Sharing Services Global Corporation’s (OTCQB: SHRG) Elepreneurs subsidiary has employed an interactive, video-based platform from VERB Technology Inc. to help it continue its significant sales growth in the direct-selling market. The company’s Elepreneurs, or independent sales force, is currently using the VERB platform in the United States, with plans to launch the platform soon in Canada (http://ibn.fm/Myltq).

The business-focused, customer relationship management (CRM), sales-enablement, proprietary platform from VERB received hundreds of five-star reviews on the Apple App Store and Google Play Store in just the first few weeks of use. The new VERB sales and marketing app offers sampling and interactive video features that support Elepreneurs’ company objectives.

“As Elepreneurs continue their North American expansion efforts, we expect to see our per-user licensed products scale in-line with that growth,” Nick Hoggan, VERB’s chief revenue officer, stated in a news release. “Additionally, with support provided by our back-end integration and interactive video features, we can ensure that Elepreneurs has the proper infrastructure that has already helped so many other companies grow their digital capabilities.”

SHRG credits its growth to the success of Elepreneurs employing a Blue Ocean selling strategy in the direct-sales market (http://ibn.fm/up2Ln). For Q1 2019, the three months ending July 31, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018 (http://ibn.fm/Eu1kw). In a 10-K SEC filing, SHRG reported record sales of $85.9 million for its fiscal year ended April 30, 2019 (http://ibn.fm/S6xaA). This represents a nine-fold increase, or a $77.5 million jump from revenues of $8.4 million the prior year.

The Blue Ocean Strategy is an approach to selling that makes the competition irrelevant by operating in and creating an uncontested market space. Strategy execution calls for exceeding expectations. The strategy stems from the book Blue Ocean Strategy by W. Chan Kim and Renée Mauborgne. “Our Q1 revenues demonstrate that our Blue Ocean Strategy has taken root and continues to grow in the direct-selling marketplace,” added SHRG CEO John “JT” Thatch.

In addition, the company has announced global expansion plans, which it will continue to implement throughout 2019. “We continue at a record-breaking pace as our dedicated and highly talented Elepreneurs continue to execute on the mission to change the direct-selling industry with best-in-class products and services,” Thatch continued (http://ibn.fm/2NB9h).

The launch of SHRG’s proprietary line of health and wellness products in December 2017 through its Elepreneurs and Elevacity Global subsidiaries was a company milestone. The line consists of three sectors: anti-aging skin care, functional beverages, and natural supplements. All are based on the D.O.S.E. product formulation of four hormones designed to promote happiness and well-being (http://ibn.fm/MCnAG). SHRG has generated $129 million in cumulative sales since the product launch.

SHRG is a Plano, Texas-based diversified holdings company that owns, operates or controls a variety of companies engaged in direct selling through independent sales contractors. The company also offers services such as energy, technology and insurance.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at  http://ibn.fm/SHRG

• Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient’s tumor
• TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes
• There’s an unmet need for a multi-omic approach (genome, transcriptome, epigenome, proteome, responseome, and microbiome), but such data is difficult to generate quickly.
• Predictive Oncology has access to historical data that competitors need at least five years to develop, which presents a multi-million-dollar market opportunity

The global cancer diagnostics market was valued at $144.4 billion in 2018 and is expected to grow at a 7.0% CAGR over the next six years on the back of increasing prevalence of oncologic cases, rapid technological advancement, and rising demand for effective screening tests. Within this broader cancer market, the Patient Derived Xenograft (PDx) segment, which involves a personalized approach to cancer treatment, was valued at $ 77.4 million in 2017 and is expected to grow at a CAGR of 16.7%, reaching $167.6 million by 2022. The driving forces behind this growth include the increasing demand for personalized medicine as well as public and private commitment to cancer research coupled with the growing R&D activities in the pharmaceutical industry.

TumorGenesis, a subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), was established in 2018 to tap into this lucrative market with its unique way to capture and culture cancer cells and screen drug combinations for personalized cancer treatment. The parent company, Predictive Oncology, aims to deliver cutting-edge services for the oncology research and profiling market.

The problem with traditional cancer research is that it relies on the procedure whereby cancer cells need to be immortalized before they can be multiplied into colonies, which are then used in further research. Immortalization, however, renders all the cells identical, resulting in homogeneous cancer cell colonies, a characteristic that is far from true for the cancer cells found in human patients. What the scientific community now realizes is that cancer tissue comes as a mixture of rapidly mutating cell variants with unpredictable behavior, which means that traditional models are not sufficiently reliable.

However, there’s a paradigm shift occurring in cancer research as Patient Derived Xenografts (PDx) cancer models are developed. These are models where the cells from a patient’s tumor are taken, cultured, and then implanted into immunodeficient mice and rats – but the challenge is to keep the cells uncompromised during the process. TumorGenesis is part of this novel line of cutting-edge research as the company developed a proprietary technology that enables tumors to be grown in the lab in a medium that tricks the tumor cells into thinking they are still in the body.

TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary to grow cancer cell colonies in a way that will not compromise their integrity – a consideration critical to the success of every cancer research. This revolutionary technology is creating an unparalleled competitive advantage for the parent company POAI, as it allows for faster and more accurate identification of tumors and the development of patient-specific treatment options. The company expects this revolutionary product to hit the market by the end of the year.

What is unique with TumorGenesis’ state-of-the-art approach to cancer research is that the company has already developed 25 validated ovarian cancer cell types that mature into uncompromised tumor colonies not only in vitro but in rats and mice, too – a formidable accomplishment as 15 out of 25 cell lines represent around 90% of all ovarian cancers discovered so far, including those most virulent and deadly.

The company is also at the forefront of immunoncological research as it developed the proprietary technology called Ovarian Cancer Kit that uses the patient’s immune system to identify cancer cell types, inhibit their growth, and categorize their response to drug treatment. These developments are possible as the parent company POAI holds the world’s largest database of tumor drug response profiles and other multi-omic data, which they leverage to develop Artificial Intelligence-powered predictive models of therapy response. This enables more rapid target drug identification and significantly improves the drug approval rates, giving the company an unrivaled competitive edge.

POAI intends to make an impact in the precision medicine business with the goal of monetizing its assets within 18 months to reach a valuation comparable to its peers of $250 million. Unlike most competitors, the company has access to historical data on clinical outcomes and can generate value to pharmaceuticals much faster, while competitors must wait at least five years for the data. With a current valuation of only about $13 million, POAI is a compelling opportunity in the rapidly growing oncology outsourcing market, estimated to exceed $24 billion by 2026.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SPRWF welcomes new senior vice president of commercial to executive team
• Joel Toguri to advance and oversee company’s provincial, retail sales operations across all brands
• New VP has two decades of experience spanning the cannabis, alcohol beverage, and apparel industries

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of cannabis companies, has announced the appointment of a new senior vice president of commercial (http://ibn.fm/2dtS0). With more than two decades of regulated industry expertise under his belt, including experience working in the cannabis space, Joel Toguri is well suited to further strengthening the SPRWF executive team. In his new role, Toguri will establish and oversee the company’s provincial and retail sales operations across all brands, including developing and driving forward-leading sales strategies, business development and retail-growth opportunities.

“Mr. Toguri’s impressive career spans the cannabis, beverage alcohol and apparel industries,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “He brings over 20 years of regulated industry knowledge and pertinent cannabis distribution expertise to Supreme Cannabis. It is a privilege to welcome a proven and skilled leader to our continuously improving team.

SPRWF’s premium wellness brand and multi-licensed processor and distributor Blissco recently launched its first product (http://ibn.fm/3Nub5) in a line of high-quality CBD oil products. This is one of many initiatives Toguri will be supporting, noted Dhaliwal.

“From the outset, Mr. Toguri will lead the launch of Blissco’s high-quality CBD oils to the Canadian wellness market and continue to build the 7ACRES brand and distribution to cement it as the leading premium flower brand nationally,” Dhaliwal continued. “The company’s talented sales team will benefit from Joel’s proven leadership abilities and strong industry network across Canada. As we grow our team, we believe our focused business and industry leading culture will continue to attract exceptional personnel like Mr. Toguri.”

The company noted that Toguri is uniquely equipped for the role, having already led sales at a large Ontario-based licensed producer in Canada, where he oversaw medical and recreational sales to patients and consumers. Before entering the cannabis industry, Toguri served as vice president of sales and operations at Southern Glazer’s of Canada, where he was responsible for establishing the company’s footprint across Canada and leading a national sales team of more than 90 people. During Toguri’s three-year tenure in that position, the company became one of the leading wine and spirits agents and brokers in Canada. Prior to his stint at Southern Glazer’s, Toguri held leadership roles at MolsonCoors and Beam Global Spirits & Wine.

Supreme Cannabis’ portfolio includes 7ACRES, its wholly owned subsidiary and multi-award-winning brand; Blissco, a wellness cannabis brand and a multilicensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a plant genetics and cultivation IP company; Medigrow Lesotho, a cannabis oil producer located in Southern Africa; Supreme Heights, an investment platform focused on CBD brands in the UK and Europe; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at  http://ibn.fm/SPRWF

• Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause
• Lexaria’s DehydraTECH platform has generated numerous patents with more pending as a way to provide quick substance delivery to the user’s bloodstream and better access through the blood-brain barrier
• Lexaria recently announced it had further improved DehydraTECH, as demonstrated in testing that showed early pilot-stage human trial participants began to note edible THC effects in under 10 minutes – more rapidly than the previous DehydraTECH formulation
• Prior technology testing has focused on animal subjects and non-psychoactive products

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is announcing further advances in its proprietary oral drug delivery platform DehydraTECH™, which is innovating edible consumption of nicotine and cannabis products as a quick-response alternative to inhalation.

Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://ibn.fm/mwAS9).

Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course of the past three years, establishing a means whereby edible consumption of certain substances can provide results at rates comparable to inhaled substances and faster than ingested substances in general.

In June, the company announced that a series of animal studies showed its DehydraTECH solution could improve on cannabidiol (CBD) delivery to the blood system by 811 percent and to brain tissue by 1,937 percent when compared with generic medium-chain triglyceride (MCT) formulations.

The latest announcement marks a new milestone in that the studies involved humans instead of animals and utilized THC instead of CBD, demonstrating further potential applications of DehydraTECH technology.

Speed of onset in the use of various drug products is regarded as a key metric of the products’ potential value, particularly where pain-relief and the relief of other physical torments are concerned. For example, nicotine is recognized as a highly addictive substance that can provoke then alleviate physical withdrawal symptoms or cravings, while certain cannabis extracts have been promoted in recent years as significant remedies for pain and muscle spasms or seizure disorders.

Inhalation has traditionally shown the greatest benefit in terms of rapid-response drug delivery benefits, but Lexaria has been passionate about delivering alternatives because of the harm substance inhalation can do to users’ lungs, as demonstrated by the history of smoking tobacco products and recent concerns about deaths and illnesses linked to vaping cannabis or nicotine products, which in turn have led health insurers to penalize customers who smoke or vape products (http://ibn.fm/x5rDh).

Because of DehydraTECH’s rapid-response capabilities, Lexaria’s technology virtually eliminates a key reason people might risk sustained injury to their lungs in using tobacco and cannabis products. Lexaria’s tech works as a complimentary product with other companies’ research and development on cannabinoids, providing Lexaria a niche as a potential collaborative team member rather than a competitor as other industry developments occur.

Lexaria’s position is further strengthened by its worldwide patents and pending patents for oral or ingestible non-psychoactive cannabinoids – it has been awarded 16 patents in the United States and Australia and is awaiting completion of the process for 60 additional patents in other countries (http://ibn.fm/W46qw).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• No Borders Inc. launches CBD LabChain blockchain platform aimed at testing market
• Global cannabis testing market projected to grow at CAGR of 13.2%, surpass $1.5 billion by 2026
• NBDR announces $3 million Reg A offering qualification

Laboratory CBD- and THC-concentration test results for retail CBD products are now on the blockchain, thanks to No Borders Inc. (OTC: NBDR). The company announced it had successfully developed and deployed a revolutionary platform for securely and immutably recording cannabinoid lab test data on its new blockchain based certification platform. The platform – CBD LabChain – was launched in November 2019 at Blockchain Expo 2019, gaining immediate exposure to a wide audience of industry leaders and professionals. No Borders, through its subsidiary No Borders Naturals, is currently the only company in the world to record 100% of its third-party, CBD lab tests on a blockchain-secured platform (http://ibn.fm/9iEwy).

The CBD LabChain platform was built to respond to two crucial consumer concerns: that consumption of a CBD product produces a positive result in an employment drug test and the uncertainty that CBD products contain their stated amount of the cannabinoid. The CBD LabChain platform was developed after extensive research and customer trials as teams from No Borders Naturals traveled coast to coast, sharing the company’s premium line of cannabinoid wellness products with more than 25,000 consumers and then assessing the results.

The CBD LabChain platform records and stores tetrahydrocannabinol (THC), cannabidiol (CBD) and other lab test data variants and make those results easily accessible via QR code and batch number linkage. Additionally, products that use CBD LabChain are offered a “Results Guaranteed with Blockchain” icon that can be directly integrated into individual product labels.

No Borders Labs, another subsidiary of No Borders Inc., believes this innovation makes CBD LabChain a powerful consumer trust tool to help overcome consumer fears and provide a clear sense of security regarding product authenticity, efficacy and potency. The company is actively working with its existing supply chain partners and third-party, lab-testing facilities to offer the trust, security and transparency of the CBD LabChain Certification to other CBD brands, extraction facilities and wholesalers around the world.

As the CBD industry matures, certification is expected to play an increasingly important role. Mounting pressure is expected from consumers and regulators to ensure that products meet safety standards and are not packaged or advertised in a misleading way. Certification and the testing that goes with it can signal product quality. As one industry commentator has remarked (http://ibn.fm/CQHAo), “Testing isn’t just out there because it’s the rules. It adds value to a business.”

As a result, the CBD-testing and certification market is forecast to grow by leaps and bounds. One industry analyst estimates the global cannabis testing market to have been $926.3 million in 2017 and projects it to surpass $1.5 billion by 2026, exhibiting a CAGR of 13.2% over the forecast period (2018-2026) (http://ibn.fm/Lp8DV).

In other company news, No Borders announced it had successfully received qualification of its Reg A offering with the SEC to raise up to $3 million. The company has filed state registrations in Colorado, Florida and New York, with several investment groups signing LOIs for partial, full or syndicated participation in the offering (http://ibn.fm/bLBw4).

No Borders Inc. is a multifaceted corporation specializing in technology, acquisitions and distribution of commercial and consumer products with a focus on reducing costs through a lean-operation business model while increasing revenue and shareholder value through technological superiority across its portfolio of assets.

Presently, No Borders has five active subsidiaries: No Borders Naturals Inc., a purveyor of health and wellness products; No Borders Dental Resources Inc., a provider of equipment and supplies to medical and dental professionals, which trades under the name MediDent Supplies; No Borders Labs Inc., which provides leading-edge tech tools to NBDR internal companies while also offering consulting, architecture and software-development services to external businesses; No Borders Funding, which provides capital and strategic funding options for No Borders group companies; and No Borders Education Inc., a provider of staff training and educational tools.

For more information, visit the company’s website at www.NBDR.co

NOTE TO INVESTORS: The latest news and updates relating to NBDR are available in the company’s newsroom at  http://ibn.fm/NBDR

• DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins
• Lexaria has 16 patents granted and over 60 patent applications pending worldwide
• DehydraTECH™ shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which will be used to advance several company-wide goals (http://ibn.fm/hGP3x).

Earlier this year, Lexaria moved into its new head office that includes a Health Canada licensed research and development laboratory that is being used to conduct world-leading research into drug delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://ibn.fm/cWL3T).

Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.

Cannabidiol is emerging as a promising compound to treat or prevent movement disorders, such as those seen in Parkinson’s disease patients, according to an article published by the National Institutes of Health (http://ibn.fm/BTruO). Extending the range of drugs available for therapeutic use to treat neurological conditions such as Alzheimer’s and Parkinson’s disease is a critical area of study since there currently is no effective treatment for these diseases, according to an article in Physics World (http://ibn.fm/C3TcM).

Lexaria’s dedication to research and development can be seen in its strong and growing intellectual property portfolio. As of August 2019, the company’s patent portfolio includes approximately 60 patent applications filed and pending in more than 40 countries around the world, with 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• CBD LabChain is the all new blockchain data security platform crafted to provide CBD brands with a transparent, immutable certification of CBD lab test results
• No Borders Labs believes CBD LabChain offers a powerful tool to overcome common consumer concerns regarding trying or using hemp-derived CBD products
• No Borders continues its early filing tradition as a listed company on the OTC Market, reporting another record quarter of revenue growth

No Borders Inc. (OTC: NBDR), a multifaceted corporation specializing in the acquisition, creation and scaling of commercial and consumer products by utilizing cutting edge technologies to reduce costs while increasing revenues and shareholder value, has launched a revolutionary blockchain utilization platform specifically designed for the CBD industry. No Borders CEO and Chairman Joseph Snyder recently presented the company’s CBD LabChain platform to a wide audience of industry leaders and professionals attending Blockchain Expo 2019 in San Francisco (http://ibn.fm/6AyQE).

“I am very proud to share our product launch of CBD LabChain,” Snyder stated in the official launch video (http://ibn.fm/EPxEZ). “Our product line, NoBordersNaturals.com, is in our humble opinion the finest line of CBD products on the market today. As of today, CBD LabChain is an immutable, secure, permanent record of all of the data, lab test results, THC amounts, CBD amounts, and other pertinent spectrum result that are in the product line that we sell to our consumers today.”

No Borders Naturals is currently the only company in the world to record 100% of its third-party lab tests on the www.CBDLabChain.com platform. However, CBD LabChain, built with a Platform-as-a-Service (PaaS) revenue model, is now available to existing market participants to record their lab test results for a per-test fee, Snyder said. Results of lab test results are easily accessible via QR Code linkage.

No Borders recently reported its family of companies achieved quarter-over-quarter revenue growth of 25.57%, increasing gross margins by 7.44% to 42.47% in Q3 2019, versus 35.03% in the previous quarter. No Borders also completed and submitted its quarterly filings early, which is now a company tradition and one that demonstrates to stakeholders an ironclad commitment to internal brand growth.

“Clearly, this filing shows that the Company is deploying capital to its brands and businesses at almost a 100% rate,” Cynthia Tanabe, COO of No Borders Inc., stated in a news release (http://ibn.fm/KumMm). “This is a strong indicator of how much faster and farther the NBDR brands can go with the addition of capital through the Company’s recent SEC filings.”

For more information, visit the company’s website at www.NBDR.co

NOTE TO INVESTORS: The latest news and updates relating to NBDR are available in the company’s newsroom at http://ibn.fm/NBDR

• New Dama financial partnership with PayWana™ integrates online banking solution with self-service technology to minimize wait times and expenses at retail locations across U.S.
• The partnership is designed to uniquely address some of the challenges cash-intensive businesses face
• Holders of Premier accounts managed by Dama can send payments via electronic ACH, wire transfer, or check to approved payees on clients’ behalf

Through a new strategic partnership, Dama Financial is integrating the online banking solution it manages on behalf of its sponsor banks, and its payment processing software Paytender(SM) with PayWana™ self-service technology, Dama Financial announced in a press release (http://ibn.fm/tg8xC). PayWana automated kiosk machines serve as a point-of-sale solution that increase average ticket size, reduce consumer wait times and expenses, and eliminate cash-handling slippage for retail locations nationwide.

The strategic partnership comes at a time when more retailers than ever are relying on innovation and technology to maximize profits. The Premier solution managed by Dama offers retail customers multiple benefits including the option to send payments via electronic ACH, wire transfer or check; to monitor transactions in real time and receive email or text alerts; to receive electronic fund and transfer money quickly between Dama-managed accounts; as well as to schedule secure cash pick-ups and delivery.

Through Paytender payment processing software, which operates like an app-based consumer wallet, users will be able to make electronic payments via QR scan technology. Its integration with the customizable PayWana self-ordering kiosk will offer a seamless workflow to cash-intensive retail businesses and an effective and intuitive interface.

According to Dama Financial CEO Dan Henry, the integration of Paytender with PayWana self-ordering kiosks will revolutionize the retail checkout process by making it automated and frictionless. “PayWana and Paytender software represents the future of consumer checkouts and will no doubt become standard technology at quick service retailers,” Henry explained.

Consumers at retail points equipped with PayWana kiosks and Dama Financial technology will therefore benefit from a fully automated and cashless checkout process using just their phones. The system will allow merchants to keep track of Paytender sales from receipt to electronic settlement from their Premier accounts.

The combination of PayWana and PayTender will fulfill customers’ expectations of shorter lines, smoother transactions online and in-person, and the ability to shop and pay at your own pace, according to PayWanna Vice President of Partnerships Ash Otocki. “Cash-intensive businesses have unique challenges that this PayWana-Paytender partnership solves,” he added.

While not a bank itself, Dama Financial provides cash-intensive industries with access to sustainable banking and payment solutions as an agent of its bank partners. Deposits held at Dama Financial partner banks are FDIC-insured up to $250,000 per account.

Using innovative technology, data and artificial intelligence, Dama Financial exceeds the compliance and regulatory requirements applicable to servicing high-risk businesses, including in the cannabis industry. Many cannabis companies are currently facing financing problems because major banks will not take them on as customers. Only one in about 30 banks or credit unions in the United States accepts a cannabis business as a customer. If accepted, these businesses are charged huge account and transaction fees, in part to help financial institutions offset the extra costs they incur (http://ibn.fm/CHqgK).

Dama Financial helps cannabis-related businesses create a safe environment for their employees and clients by reducing cash on hand, enabling them to pay their vendors and employees either electronically or by check, and receiving fund transfers effortlessly (http://ibn.fm/ALx2C).

Dama Financial is an agent of its partnering financial institutions and licensed money transmitters. Customer funds are deposited into a custodial account maintained for the benefit of account holders at one or more FDIC-insured institutions. Fees, terms and conditions apply to depositing funds into and using an Account managed by Dama. Account Terms and Conditions and Fee Schedule are available upon registration to access the online application.

For more information, visit the company’s website at www.DamaFinancial.com

NOTE TO INVESTORS: The latest news and updates relating to Dama Financial are available in the company’s newsroom at http://ibn.fm/Dama

• HTC acquires California-based Kase Farma Inc.
• HTC Extraction Systems announces tolling contracts, project progress and more
• Hemp-derived CBD market set to grow to $22 billion by 2022

With the acquisition of a company engaged in the extraction, purification and wholesale distribution of hemp-based cannabinoid extracts, HTC Extraction Systems (TSX.V: HTC) has bolstered its output capability and institutional knowledge considerably. The acquired entity – Kase Farma Inc. of Ceres, California – is currently expanding and upgrading its extraction, refining and processing operations. Kase Farma will enter into an intellectual property licensing agreement with Starling Brands Inc., the vendor. Under this licensing agreement HTC’s Canadian facility will also be the recipient of this intellectual property (http://ibn.fm/0WcJv).

The demand for cannabinoids is climbing. But since cannabis remains a Schedule I drug under the Controlled Substances Act of 1970, extraction of cannabinoids from cannabis poses serious legal risks. This may soon change. Several bills have been tabled in Congress to move cannabis to Schedule III, most memorably the Marijuana 1-to-3 Act. In the meantime, extracting cannabinoids from hemp – HTC Extraction Systems’ forte – avoids running afoul of federal law.

Kase Farma is active in the cultivation of hemp as well as the formulation and extraction of cannabinoids from hemp; the company is also licensed in the State of California to perform activities in those areas. At present, the company operates out of a 22,000-square-foot manufacturing facility and is currently implementing a scaled-up, high-throughput extraction facility that will utilize identity-preserved-grown (IPGrowTM), hemp-based cannabinoid biomass. IPGrowTM, according to the U.S. Department of Agriculture definition, preserves the integrity of identifying information “to ensure what is grown in the field is what the buyer receives.” Kase has partnered with a number of highly regarded IPGrowers that will supply the high-quality biomass required for the therapeutic, wellness and recreational product lines.

Kase Farma strives to deliver health and wellness benefits of CBD, CBG, CBN and other cannabinoids via the production of high-quality, premium hemp products through best of class methods while sustaining an unrelenting commitment to people, community and the environment. Kase Farma will also provide white-label manufacturing for other cannabinoid suppliers.

Demand for cannabinoids is growing rapidly. Industry analyst Brightfield Group projects the hemp-derived CBD (cannabidiol) market will grow to $22 billion by 2022 (http://ibn.fm/a6VYL). HTC is poised to benefit from the booming market. The company’s extraction technology — the Delta Purification system — uses hemp, most of the legal restrictions on which were removed by the last farm bill. Now hemp can be grown freely with the proper license, however, hemp-derived products can be transported across state lines for commercial or other purposes, and hemp-derived products may be sold provided these activities are done in a manner consistent with the law.

In October, HTC announced the completion of the 19,000-square-foot facility that will house its quality-assurance testing and product-development laboratories as well as its extraction and formulation-processing operations. The facility is located 17 miles southeast of Regina, Saskatchewan, at HTC’s Port Lajord location. The facility is in the final stages of required modifications to qualify as GMP Euro compliant and after completion will be one of the highest-performance and highest-product-quality extraction and refining facilities in Canada. In addition, HTC has completed the construction of its 27,000-square-foot, hemp-biomass processing and storage building, to be utilized for the storing of extraction-ready biomass (http://ibn.fm/YNScf).

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• Company reports increased revenue over last year’s Q3 numbers
• Key operational highlights point to even stronger revenue growth moving into 2020
• Sigma Labs’ pioneering software provides essential element to spur additive manufacturing into the next industrial revolution

Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D-printing industry, reported its financial and operational results for the third quarter ended Sept. 30, 2019 (http://ibn.fm/jmBVm). The company noted that recent progress with original equipment manufacturers (OEMs), end users and additive-manufacturing integrators positions SGLB for strong revenue growth in 2020.

“The third quarter of 2019 was highlighted by continued success in engaging both OEMs and end users as PrintRite3D(R) customers, driving continued industry awareness and developing promising commercial opportunities,” said Sigma Labs chairman and CEO John Rice. “Notably, we were recently selected by a major Japanese OEM machine-tool manufacturer entering the commercial, metal 3D-printing market, as well as an unnamed major international OEM machine manufacturer, to deploy PrintRite3D systems for their respective evaluation programs. We believe a partnership to integrate our technology at the OEM level for any major additive manufacturing machine OEM, such as those we are in evaluations with now, could drive notable license revenue growth in the short term and very significant pass-through revenue from the OEM’s customers in the mid and long term.”

He continued, “We are pleased and encouraged by the robust interest we continue to see from industry OEMs and look forward to providing our shareholders with an update as these evaluations progress over the next several months.” This increased interest from OEMs stands to translate into lucrative gains for SGLB. Market indications continue to trend upward, as the global additive manufacturing market is expected to exceed more than $6.50 billion by 2024 and will grow at a CAGR of more than 13% in the given forecast period (http://ibn.fm/YkU49).

In its Q3 2019 report, Sigma Labs pointed to several significant operational milestones, including:

• Awarded two-machine contracts and selected for a Phase 2 test and evaluation program of PrintRite3D in-process, quality-assurance software by a leading global-energy technology company
• Selected by major Japanese OEM machine-tool manufacturer for a test and evaluation program of PrintRite3D real-time melt pool analytics
• Awarded RTE contract by VTT Technical Centre of Finland to install PrintRite3D at the VTT 3DMetalprint Centre for Additive Manufacturing
• Selected by a major international OEM machine manufacturer to deploy two PrintRite3D quality-assurance software programs as part of an evaluation process for a broader rollout
• Selected by Airbus to deploy the PrintRite3D version 5.0 software product into a fusion printer as part of a testing and evaluation program ahead of a larger potential commercial rollout throughout the Airbus organization.

In addition, this week SGLB’s chief technology officer Darren Beckett presented and demonstrated PrintRite3D at Formnext 2019, the leading global exhibition on additive manufacturing, held in Frankfurt, Germany.

“Additive manufacturing is, in our mind, undoubtedly the next industrial revolution,” said Rice. “And we are on the forefront of revolutionizing an essential element for its widely forecast leap to serial manufacturing. The flexibility inherent to additive manufacturing, combined with the increased quality and decreased risks, waste and costs accomplished with our PrintRite3D technology, create an unbeatable combination.”

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D advanced manufacturing technologies. SGLB’s advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB